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ABSTRACT 
 
Secondary spread of cancer to bones is commonest and frequent phenomenon and enhances the 
need of special care for sufferers. Bone metastases mostly are the first complication of different 
variety of cancers which increase the need of care and expensive facilities. Blood dissemination is 
another common route, might be due to the venous drainage from visceral organs directly into the 
axial bones. CA 15-3 is a mucinous tumor markers derived from MUC1 gene, provides better guide 
line about the treatment, recurrence and prognosis. 
Aim: Aim of the study was to signify the role of tumor marker CA15-3 in metastatic breast cancer. 
Original Research Article 
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Methods: Hundred females of breast cancer (any age) with different stages of breast cancer with 
and without bone metastasis were tested for their serum level of CA 15-3 (biomarker of breast 
cancer). Bone scan was done to check the secondary metastasis to bones. Intravenous dye 
Ttechnicium 99 MDP has been used. Serum levels of ca15-3 were measured with the help of 
Gama Counter with computerized system and IRMA kit (Immunoradiometric Assay) by 
IMMUNOTECH. Ultrasound of whole abdomen and X ray/CT scan were used to detect liver and 
pulmonary metastasis respectively.  
Results: Results indicate a high statistical significant relationship between bone metastasis and 
elevated levels of tumor marker CA 15-3 in breast cancer patients. Elevated levels of tumor marker 
CA 15-3 is strongly correlated with positive bone scan. An elevated level of tumor marker CA 15-3 
is also correlated with positive pulmonary metastasis CA 15-3 is highly sensitive to detect bone 
metastasis and also sensitive to detect pulmonary metastasis. A lesser extent of high CA 15-3 
serum levels is determinant of liver metastasis. Bone scan is essential tool to detect bone 
metastasis but need assistance of chemical biomarkers.  
Conclusions: CA 15-3 as a tumor marker proved a help full determinant of tumor burden in 
metastatic breast cancer. Its significance is more to detect bone metastasis than to pulmonary and 
then to liver metastasis. Future studies upon CA15-3 in association with imaging techniques and 
other organ related specific tumor markers to detect specific metastasis or overall body tumor 
burden will be blessing for patients and physicians. 
 
 
Keywords: Tumor marker CA15-3; bone; liver and lung metastasis; bone scan; breast cancer. 
 
1. INTRODUCTION 
 
Cancer is a main reason of mortality in 
developed and undeveloped countries. Main 
reasons are the raise in world population and 
aging especially in low socioeconomic countries 
which accounts up to 82% of the world’s 
population. Estimated new female breast cancer 
cases by age in USA, 2015 were 60,290 of 
ductal carcinoma in situ and 231,840 of lobular 
carcinoma in situ. Total estimated deaths by age 
in USA 2015 were 40,290 [1]. According to 
collected data of 2012 about 14.1 million new 
cases and 8.2 million deaths occurred because 
of breast cancer. Lung and breast cancer are top 
most cancers that ultimately end on death in both 
genders worldwide [2]. Secondary spread of 
cancer to bones is commonest and frequent 
phenomenon and enhances the need of special 
care for sufferers [3,4,5,6]. Bone metastases 
mostly are the first complication of different 
variety of cancers which increase the need of 
care and expensive facilities. Different tumors 
have different specific sites of metastasis
.
 [4 
Metastasis up to bones and consecutive bone 
related complication like fracture, hypocalcaemia, 
pain and declines in mobility and performance 
status are common in breast cancer, prostate 
cancer and multiple myeloma [5,6,7]]. The 
disease stage and the biological properties of the 
tumor are the basis of secondary metastasis. 
Influencing prognostic factors  for the recurrence 
of cancer are the size of the tumor, nodal 
involvement, presence of lymphovascular and 
perineural invasion, tumor grade, receptor status 
of hormones like estrogen and progesterone, and 
HER2 (human epidermal growth factor receptor-
2). Metastatic breast tumors to different organs 
represent heterogeneous characteristics and 
biological behavior. A recent study shows that 
the hormone receptor and HER2 positivity or 
negativity, site of the metastasis (visceral vs. 
non-visceral), performance status, disease-free 
survival period, initial adjuvant treatment  and the 
initial treatment given to the patients of 
secondary metastatic breast cancer are the 
factors that influence the outcome [8].  
 
Most affected site is the axial skeleton secondary 
to breast cancer. Blood dissemination is another 
common route, might be due to the venous 
drainage from visceral organs directly into the 
axial bones. According to postmortem research 
on animals and humans by Batson [9] confirmed 
that venous blood from the breasts and pelvic 
organs, like the prostate, drained into the vena 
cava, and vertebral-venous  (Batson’s) plexus of 
vessels as well, from the pelvis up to the epidural 
and perivertebral veins. Direct extension of 
vascular routes from viscera to axial skeleton 
describes the involvement of axial skeleton in 
breast and prostate cancers. Structural 
interaction between cells, molecules and 
chemicals of bones are responsible for cancer 
growth within bones. [10,11] Bone scintigraphy 
with technetium-99 m–labeled diphosphonates is 
a commonest radionuclide procedure which is 
not only specific but also sensitive that is why 
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used as a screening tool for many pathologic 
conditions. Some pathological conditions which 
cannot pick by other imaging techniques can be 
diagnosed with bone scan. Secondary Bone 
metastases showed as hot spots but some times 
less echogenic. Other bone injuries can be 
detected, in the absence of other radiographic 
findings. Bone fractures can be detected by bone 
scan within 24 hours, except osteopenia in older 
patients [12]. About 75% symptomatic malignant 
cases easily detected by bone scintigraphy but 
25%–45% of asymptomatic patients with 
malignancy also have positive bone scan for 
metastases [13,14,15]. Result of a study showed 
that breast cancer with multiple bone metastases 
is associated with advanced staging. Patients 
with concurrent lesions of rib and other sites had 
a significantly higher rate of metastatic disease 
than those with only other site lesions. Rib 
metastasis incidences were higher in cases with 
multiple rib lesions, lymph node metastasis, and 
lesions of both ribs. [16] Use of tumor markers is 
success full molecular tools to defining early 
diagnosis, prognosis, and treatment plan [17]. 
CA 15-3, CA 459 etc are mucinous tumor 
markers derived from MUC1 gene, and are 
useful as diagnostic tumor markers in cancer. 
[18] (Kufe, 2012). Clinically they provide better 
guide line about the treatment and prognosis. CA 
15-3 consists of 3 domains and 2 subunits. The 
extracellular subunit contains 20 amino acid 
residues. Subunits of CA 15-3 contain functional 
site and important in evaluation of significance of 
CA 15-3 in breast cancer [19,20,21]. Higher 
values of CEA and CA 15-3 found before surgery 
showed higher mortality, (P=0.0001 for both 
markers). A decline of CA 15-3 of more than 33% 
was also associated with worst outcome which 
might be recurrence or death (death from 
disease P=0.007; disease free survival 
P=0.0087). Comparatively CA 15-3, the CEA 
decline alone, independent of levels before 
surgery was strong indicator of recurrence and 
mortality [22]. Elevated CA 15-3 level indicates 
that treatment regimen is not suitable. CA 15-3 is 
a serum based and noninvasive test and easy to 
perform. Kurebayashi et al. [23] stated that 
higher levels of ca15-3 before start of treatment 
and change in post therapy levels linked with 
prognosis. CA 15-3 values predicts the outcome 
of disease and treatment [24]. Role of CA15-3 as 
a marker at molecular and pathological level and 
its significance to determine response of 
treatment as well as chances of recurrence need 
further work. In a recent review Duffy et al. [25] 
decided that in advanced stages CA15-3 is 
essential to check response of treatment. Expert 
panels like NACB and EGTM emphasize to 
check CA 15-3 level in monitoring treatment 
response [26,27]. Otherwise ASCO panel do not 
think it is as an important diagnostic and 
prognostic tool.   
 
Aim of the study was to signify the role of tumor 
marker ca15-3 in metastatic breast cancer. 
 
2. METHODOLOGY  
 
2.1 Selection of Patients 
 
Data were collected by trained medical 
physician, nurses and laboratory persons. 
General information from each subject was 
collected through a standard questionnaire 
including participant’s name, age, education, 
monthly income and living style, ethnicity, 
gravidity, para, abortions, clinical sign and 
symptoms, material status, family history, etc. 
We explained the objectives and important 
features of the study to all patients prior to the 
start of study and their consent was taken. 
 
2.2 Blood Collection 
 
Before interviewing and blood collection a verbal 
consent was taken from each respondent. 
Venous blood was withdrawn for the 
investigation. First the skin was cleaned 
thoroughly with sterilized with 70% Isopropyl 
Alcohol swab and dried before puncturing. 2 ml 
of blood taken from the antecubital vein by using 
5cc disposable syringe (Becton Dickinson, PAK 
PVT Ltd). The blood sample was transferred to 
labeled test tube. And then tubes were marked 
with codes and immediately taken to the lab. 
 
2.3 Inclusion Criteria 
 
Hundred females of breast cancer (any age) with 
different stages of breast cancer with and without 
bone metastasis were tested for their serum level 
of CA 15-3 (biomarker of breast cancer). Bone 
scan was done to check the secondary 
metastasis to bones. During the study Chemo 
therapy and radiotherapy were allowed 
accordingly and most of patients have passed 
through the first three cycles of chemotherapy 
and radiotherapy. 
 
2.4 Exclusion Criteria 
 
All the known cases of primary bone diseases, 
lung diseases and liver diseases were excluded 
from study. 
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2.5 Bone Scan 
 
Bone scan was done on Siemen E Cam scanner 
with accessories. (Figs. 1A & B) Intravenous dye 
Ttechnicium 99 MDP has been used. This test 
helps to see if a cancer has metastasized to 
bones and is useful because it provides a picture 
of the entire skeleton. For this purpose, 20/mci 
(dose) of radioactive material (technetium 99) 
was injected into a vein (intravenously or IV). The 
substance settles in areas of damaged bone 
throughout the entire skeleton over the course of 
a couple of hours. (Six hours to twenty four 
hours). Patient lied on a table for about 30 
minutes while a special camera detected the 
radioactivity and created a picture of the 
skeleton.  
 
2.6 Ultraosund  
 
Simple Grey scale ultrasound was done on 
Toshiba machine model no Aplio 500.  
 
2.7 X Ray /CT Scan Chest  
  
X ray done on 14x17 Samsung Flat Panel X-Ray 
machine. 
 
CT scan chest done on Toshiba Aquilion 8. 
 
2.8 Biochemical Parametre 
 
2.8.1 CA15-3  
  
Serum levels of ca15-3 were measured with             
the help of Gama Counter (Fig. 1C) with 
computerized system and IRMA kit 
(Immunoradiometric Assay) by IMMUNOTECH, 
REF, and IRMA 2397. We collected the serum in 
simple tubes and stored at <-18 degree 
centigrade. First  diluted the samples and control 
by adding 10/up of samples or control in to glass 
tubes and then adding to each tube 500/ul of 
diluents and then shaken gently before use. To 
coated tubes we added 200/up of calibrator, of 
diluted sample or of diluted control then 
incubated for two hrs at 18- 25 degree centigrade 
with shaking at 400 rpm. Then aspirated the 
content of each tube, then washed twice with 
2/ml of distilled water. After that we carefully 
aspirated. After aspiration we added 200/ul of 
tracer in each tube, incubated for 1 hr at 18-25 
/degree centigrade with shaking at 400 rpm. For 
counting the bind antigen antibody, aspirated the 
content of each tube, then washed twice with 
2/ml of distilled water. Then counted for 1 minute 
both bound B cpm and total cpm. We also added 
the 200/ul of tracer in 2 additional tubes to obtain 
total cpm. 
 
  
 
Fig. 1A & B.  Siemens E Cam Bone Scan Machine with the permission of Kiran Hospital, 
Karachi 
  
 
 
Fatima et al.; JCTI, 4(3): 1-12, 2016; Article no.JCTI.28440 
 
 
 
5 
 
 
 
Fig. 1C. Gamma Counter with coputerized system for the assay analysis of CA15-3.  
With the permission of KIRAN  hospital, karachi 
 
 
2.9 Statistical Analysis 
 
The data feeding and analysis was done on 
computer package SPSS (Statistical Packages of 
Social Sciences) version 11.0. Clinical 
characteristics will be summarized in terms of 
mean ± S.D, SEM, for quantitative variable. 
Student t-test was used for comparison of 
quantitative variables in between bone scanning 
positive and negative groups. For statistical 
analysis only p-value <0.05 are considered 
significant.  
 
3. RESULTS  
 
Comparison of general characteristics age, 
marital status and parity showed no statistical 
significant analysis among bone scan positive 
and negative groups [Table 1]. Analysis of TNM 
staging in bone scan positive group showed 
maximum cases of t4n1m1 and t1n0m0 which 
are 13 in number then stage t3n1m1 was 
predominant, 11 cases and then t2nxm0 (8). 
None of stage t1nxm0, t2n2m0, t2n3mx, t3n2m0, 
t3n2mx related case was found. Among bone 
scan negative cases maximum cases of stage 
t2n0m0 (14) and then stages t2n0m0, t1n1m0 (9, 
8) were found.  No case of stage t4n1m1 was 
found [Table 2]. 
 
A highly significant relationship was found 
between bone metastasis and elevated levels of 
tumor marker CA 15-3 in serum of breast cancer 
patients. Results are statistical significant. Serum 
CA 15-3 levels are remarkably high in cases with 
age group below 30 and above 70 years.  Paired 
with bone scan CA 15-3 levels confirms the bone 
metastasis in breast cancer patients. Moderate 
increase of CA 15-3 levels were found in 
perimenopausal and menopausal patients (40-69 
years). Age group of (30-39 years showed slight 
lower tendency of bone metastasis and increase 
in serum CA 15-3 levels). Some cases of breast 
cancer without bone metastasis also showed 
high serum levels of tumor marker CA 15-3 
which is statistical insignificant [Table 3].      
Number of Liver and Lung metastasis were more 
or less same among bone scan positive and 
negative groups and were not statistically 
significant. P value for liver metastasis was near 
to significant level (0.06) [Table 4]. CA15-3 
serum levels found higher in positive liver 
metastasis patients among both groups of bone 
scan. P value (.098) is near the level of statistical 
significance [Table 5]. A statistical significant 
relationship was found between bone metastasis 
and elevated levels of tumor marker CA 15-3 in 
serum of breast cancer patients, P value (.016) 
[Table 6]. 
 
4. DISCUSSION 
 
Cancer is the worldwide growing menace for 
health and responsible for death as a second 
number killer. The incidence rate of mortality in 
developed and underdeveloped countries is 
more or less same or still increasing.  Reason 
may be the increase life span and common 
exposure to risk factors [28]. Globally Breast 
cancer is counted as commonest cancer and 
having more than 1,300,000 new cases and 
450,000 demises every year worldwide [29]. 
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Table 1. General characteristic 
 
  
  
Bone scanning P-value 
Positive 
(n=100) 
Negative 
(n=100) 
Age in years  
Under 30 8 5 0.732 
30-39 20 21 
40-49 32 35 
50-59 22 27 
60-69 12 9 
70 & above 6 3 
Mean ± S.D ± SEM 46.7 ± 12.49 ± 1.26 46.1 ± 10.47 ± 1.26 0.733 
Marital status  
Married 94 96 0.516 
 Unmarried 6 4 
Parity 
Alive children 
  
None 14 7  
0.209 
 
 
1-3 23 27 
4-6 40 49 
7 & above 23 17 
Abortion  
None 59 59  
0.320 
 
 
1 21 29 
2 15 11 
3 5 1 
* Statistically significant p<0.05 
 
In 2012, l, 52,680 new cases of breast cancer is 
supposed to report and an expected risk of 52 
cases out of 100,000 women [30]. Prevalence 
and mortality rate is higher in growing age group. 
50% percent of half of the females with age of 65 
and onward die because of breast cancer [31]. If 
the patient survives breast cancer can lead to 
severe illness causes and even permanent 
disabilities. Aggressive behavior of cancer 
tissues may lead to a decrease in life expectancy 
[32]. 
 
During our study CA15-3 serum level was found 
significantly high in bone scan positive cases 
especially cases with advance staging, P, value 
is statistically significant , P<0.01. Serum levels 
of CA 15-3 were found high also in some 
negative cases of bone metastasis which was 
not statistically significant, but important from the 
morbidity point of view. Comparison of serum 
levels of CA 15-3 in patients of different age 
group with and without bone metastasis showed 
that extreme of age (under 30 & above 70 years 
shows) greater tendency of bone metastasis and 
related morbidity. Moderate increase of CA 15-3 
levels were found in perimenopausal and 
menopausal patients (40-69 years). Age group of 
(30-39 years shows slight lower tendency of 
bone metastasis and increase in serum CA 15-3 
levels). Lung and liver metastasis is common in 
breast cancer. Number of Liver and Lung 
metastasis were same among bone scan positive 
(22) and negative groups (12 and 14 
respectively). P value for liver metastasis was 
near to significant level (0.06). CA15-3 serum 
levels found higher in positive liver metastasis 
patients among both groups of bone scan. P 
value (.098) is near the level of statistical 
significance. A statistical significant relationship 
was found between lung metastasis and elevated 
levels of tumor marker CA 15-3 in serum of 
breast cancer patients, P value (.016). Study 
provides that in breast cancer bones are 
commonest sit of metastasis then lung and then 
liver. Raised CA 15-3 levels in serum of patients 
can predict the metastasis to these sites. 
 
A comparative study regarding the sites of breast 
cancer metastasis declares the longer survival 
period for bone and lung metastasis patients 
than liver metastasis. Brain metastasis showed 
least survival period. Post-menopause, diabetes 
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mellitus, lymphovascular invasion positivity, high 
disease grade, and multiple organ metastases 
are related to poor disease out come. Bone only 
spread of cancer is appeared a better predictor 
of survival. Lungs are also a second common 
site of breast cancer metastasis [33]. 1Radiation 
Oncology Department, Cumhuriyet University 
School of Medicine, Sivas, TR–58140, Turkey  
2Medical Oncology Department, Cumhuriyet 
University School of Medicine, Sivas, TR–58140, 
TurkeyAustin J Med Oncol - Volume 1 Issue 2 – 
2014. 
 
Table 2. TNM staging in bone scan positive 
and negative cases of breast cancer 
 
TNM staging in bone 
scan positive cases 
TNM staging in bone 
scan negative cases 
t1n0m0 13 t1m0n0 9 
t1n1m0 4 t1n1m0 8 
t1nxm0 0 t1nxm0 4 
t2n0m0 8 t2n0m0 14 
t1nxm0 4 t1nxm0 1 
t2n1mx 5 t2n1mx 1 
t2n1m0 4 t2n1m0 4 
t2n2m0 0 t2n2m0 4 
t2n2mx 1 t2n2mx 2 
t2n3mx 0 t2n3mx 2 
t2nxm0 8 t2nxm0 4 
t2nxmx 1 t2nxmx 2 
t3n1m1 11 t3n1m1 4 
t3n1mx 2 t3n1mx 4 
t3n2m0 0 t3n2m0 2 
t3n2m1 1 t3n2m1 2 
t3n2mx 0 t3n2mx 2 
t3nxmx 4 t3nxmx 2 
t4n1m1 13 t4n1m1 0 
t4n1mx 2 t4n1mx 2 
t4n2m1 3 t4n2m1 2 
 
Increased serum CA 15-3 levels in advanced 
stages indicates its role as a prognostic marker 
as well. CA 15-3 is transmembrane protein and 
derived from MUC- 1, gene exists as a dimmer of 
two subunits. Two proteases, ADAM17, and 
MTMMP1 are responsible for hydrolysis [34,35]. 
Its expression is different on surface of different 
cell types, but it is over expression is seen in 
90% cases of breast cancer [36]. An increase in 
CA 15-3 serum levels before surgery is strongly 
suggestive of relapse and demise. Different 
study plans are need of time to establish the 
prognostic role of CA 15-3 before surgery in 
cases of breast cancer. If it proved as an 
established prognostic tumor marker, then it 
must be a part of investigation prior to select the 
treatment regimen [37]. There are many risk 
factors which facilitates breast cancer. Elevated 
serum CA 15-3 levels and misbalance of ER, PR 
and Her2/NEU are thought to be main causative 
factors of breast cancer. The hormonal 
misbalance may be responsible for aggressive 
uncontrolled cell division. Alteration in active site 
of hormones in combination with interaction of 
extra cellular domain of CA 15-3 with α domain 
of ER may be responsible for metastasis in 
breast cancer through stimulation of RAS protein 
Pathway [38]. Elevated CA 15-3 serum level at 
PC and late tumor stage indicate a failure of 
response to chemotherapy. There is an inverse 
relation between CA15-3 level and response to 
chemotherapy, tumor size and lymphovascular 
spread. Kurebayashi et al. [39] proved that more 
than 20% post chemotherapy decrease in CA 15-
3 levels is an indicator of good prognosis and 
lessen the disease progression duration. Raised 
CA 15-3 levels shows bed prognosis after initial 
cycles of chemotherapy in breast cancer with 
local invasion. Simultaneous increase in CA15-3 
levels after chemotherapy and presence of        
HER 2 receptors with local lymphovascular 
involvement is indicating greater morbidity [40].   
A study upon comparison of different tumor 
markers such as CEA, Ca15.3, lactate 
dehydrogenase  and CA 15-3  to analyze their  
combine and alone prognostic and predictive 
values showed that CA15-3 alone  has an 
established role  as a prognostic tumor marker.  
Role of other markers like CEA and LDH were 
fluctuating among different patients in metastatic 
breast cancer. Research also had the objective 
to assess the effect of high levels of tumor 
marker on survival duration. Raised levels of CA 
15-3 were found to be a prognostic factor 
affecting survival duration [41].  
 
Another research regarding the significance of 
CA15-3 in recurrence of breast cancer was 
showed that it was elevated in approximately half 
of bone-only metastases and in all of the         
liver-only metastases. In the pulmonary-only 
recurrences, the marker value was not elevated 
[42]. A multivariate analytical study to detect 
prognostic significance of CA15-3 and CA-125 in 
metastatic breast cancer proved the CA 15-3 and 
CA-125 powerful prognostic factor and indicator 
of visceral metastasis in advance stages of 
breast cancer [43]. 
 
Our study signifies the role of bone scintigraphy 
for detection of bone metastasis in combination 
with tumor marker CA 15 -3. Results showed that 
patients with positive bone scan were at advance 
stages of disease. 
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Fig. 2. Serum CA15-3 levels in subjects with positive- and negative bone scan 
Fig shows comparison of serum Ca15-3 levels in the subjects of different age groups with positive and negative 
bone scan. Comparison showed significantly increased serum Ca15-3 levels in positive bone scan subjects as 
compared to negative bone scan group. 
Statistically Significant. *P<0.01 
 
Table 3. Biochemical parameter in bone scanning positive and negative case 
 
Biochemical  
tumor marker 
Bone scanning (Positive) 
(n=100) 
Bone scanning (Negative) 
(n=100) 
P value 
Mean S.D SEM Mean S.D SEM 
CA 15-3 127.2** 151.16 15.19 54.1 71.97 7.23 0.001 
** Statistically significant p<0.01 
 
Table 4. Physical parameter in bone scanning 
positive and negative case 
 
 
Bone scanning P-value 
Positive 
(n=100) 
Negative 
(n=100) 
Liver  
metastasis 
22 12 0.060 
Pulmonary  
metastasis 
22 14 0.141 
** Statistically Significant p<0.01 
 
According to the NCCN clinical practice 
guidelines in oncology for breast cancer, 
international guidelines for management of 
metastatic breast cancer from the European 
School of Oncology (ESO)-MBC Task Force [40], 
as well as earlier studies [44,45,46,47,48] 
Confirmatory Imaging techniques secondary to 
bone metastasis are CT or MRI. Hot spots on 
bone scan are supposed the benign lesions by 
physicians and no need of other imaging 
techniques. Patient should be keep on only on 
followed up. If there is any suspicion of 
metastatic disease on bone scan, CT, MRI, PET 
scans are the appropriate choices. Majority of 
bone scans are performed with intention to 
detect malignancy, especially in malignancies of 
the breast, prostate gland, and lung. Bone 
imaging modalities are important for cancer 
histopathological staging and management. This 
technique is useful to pick skeletal abnormalities, 
and numerous studies have confirmed that it is 
considerably more sensitive than conventional 
radiography for this purpose. [49,50,51,52]. 
About 75% of patients with malignancy and pain 
have abnormal bone scintigraphic findings. 
Perhaps even more importantly, 25%–45% of 
asymptomatic patients with malignancy have 
scintigraphic evidence of bone metastases. The 
usual pattern consists of increased radiotracer 
deposition in areas of osteoblastic reparative 
activity in response to tumor osteolysis 
[53,54,55]. Bone scintigraphy is a popular and 
important imaging modality and will likely remain 
so for the foreseeable future. Although bone 
scintigraphy is not specific, its exquisite 
sensitivity makes it a useful screening procedure
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Table 5. Biochemical parameter in bone scanning positive and negative case 
 
Biochemical  
tumor marker 
Bone scanning (Positive) 
(n=100) 
Bone scanning (Negative) 
(n=100) 
P value 
Liver metastasis positive 
n = 22 
Liver metastasis positive 
n =12 
Mean S.D SEM Mean S.D SEM 
CA 15-3 127.48 139.11 1.39 161.39 148.60 1.48 0.0985 
** Statistically significant p<0.01 
 
Table 6. Biochemical parameter in bone scanning positive and negative case 
with positive pulmonary metastasis 
 
Biochemical  
tumor marker 
Bone scanning (Positive) 
(n=100) 
Bone scanning (Negative) 
(n=100) 
P value 
Pulmonary metastasis positive                
n = 22 
Pulmonary metastasis positive             
n =14 
Mean S.D SEM Mean S.D SEM 
CA 15-3 145.08 83.8 0.83 51.76 375.50 0.37 0.0162 
** Statistically significant p<0.01 
 
for many pathologic conditions. Moreover, some 
conditions that are not evident on anatomic 
images can be diagnosed with radionuclide bone 
imaging [56]. 
 
5. CONCLUSIONS 
 
Elevated levels of tumor marker CA 15-3 is 
strongly correlated with positive bone scan. 
 
Bone scan is highly sensitive to detect bone 
metastasis but need assistance of chemical 
biomarkers. 
 
CA 15-3 as a tumor marker proved a help full 
determinant of tumor burden in metastatic breast 
cancer. Its significance is more to detect bone 
metastasis than to pulmonary and then to liver 
metastasis. 
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